{"entity":{"id":"pheon-therapeutics","kind":"company","name":"Pheon Therapeutics","aka":[],"tldr":"Pheon Therapeutics, of London, designs antibody-drug conjugates against an undisclosed target overexpressed across a wide range of solid tumours; its lead carries eight topoisomerase 1 inhibitor molecules per antibody and showed a wide therapeutic index preclinically. It raised a 120 million dollar Series B in 2024 and has entered early human trials.","summary":"Pheon Therapeutics is a London-based antibody-drug conjugate specialist building a pipeline of ADCs against undisclosed new targets and clinically validated ones, using either its proprietary payload platform, which acts through a mechanism distinct from established payloads, or established linker-payloads. Its first three assets address an undisclosed novel target that is highly overexpressed across a wide range of solid tumours; the lead uses a DAR8 topoisomerase 1 inhibitor linker-payload and the company reported an unusually wide preclinical therapeutic index, with a first phase 1 trial planned from 2024. By September 2025 the company described itself as clinical-stage. In May 2024 Pheon closed a USD 120 million Series B led by TCGX with BVF Partners, Lightspeed and Perceptive Advisors alongside existing investors Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://pheontx.com/"},{"label":"Series B press release","url":"https://pheontx.com/pheon-therapeutics-announces-120m-series-b-financing-to-fund-development-of-its-differentiated-adc-pipeline/"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":["adc","topoisomerase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Lead target undisclosed. Series A (2022) not fetched and omitted."],"hq":"London","country":"GB","companyType":"biotech","website":"https://pheontx.com/","stage":"startup","investors":["tcgx","lightspeed-venture-partners","perceptive-advisors","atlas-venture","forbion"],"funding":[{"round":"Series B","year":2024,"amountUsd":120000000,"source":"https://pheontx.com/pheon-therapeutics-announces-120m-series-b-financing-to-fund-development-of-its-differentiated-adc-pipeline/"}]},"route":"/companies/pheon-therapeutics/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"company":[{"id":"atlas-venture","kind":"company","name":"Atlas Venture","route":"/companies/atlas-venture/"},{"id":"forbion","kind":"company","name":"Forbion","route":"/companies/forbion/"},{"id":"lightspeed-venture-partners","kind":"company","name":"Lightspeed Venture Partners","route":"/companies/lightspeed-venture-partners/"},{"id":"perceptive-advisors","kind":"company","name":"Perceptive Advisors","route":"/companies/perceptive-advisors/"},{"id":"tcgx","kind":"company","name":"TCGX (TCG Crossover)","route":"/companies/tcgx/"}]}}